SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

Rising number of U.S. pediatrics receiving proton therapy Treatment yields unique benefits for young cancer patients

Mevion partners with Philips to improve proton therapy treatment New technology only takes a few seconds to scan tumor

Kentucky Trailer acquires Advanced Mobility to expand medical footprint Together they look toward a greater international presence

Screening with tomo and mammo leads to 405 fewer false positives per 1,000 women The cost of the two is relative to cost of mammo alone

Comparing catheters for early stage breast brachytherapy Is the treatment underutilized? The BC5 Project thinks so.

Health Gorilla Marketplace expands in effort to demystify ACO and IPA options Version 2.0 adds seven new vendor categories to its market reach

Siemens' new MR kit may reduce pediatric anxiety and need for sedation Could lead to reduced costs and increased efficiency

400 experts gather at Focused Ultrasound Foundation's annual meeting 200 scientific presentations show promising new research

380 hospitals execs weigh in on the future The quest to provide better care with fewer resources

Companies develop pediatric medical devices to compete for $50,000 prize Will the smallest of patients finally have more options?

Will CMS revise its coverage policy for new PET agents?

by Loren Bonner , DOTmed News Online Editor
The Centers for Medicare and Medicaid Services is in the process of reconsidering its coverage determination for PET radiopharmaceuticals outside of the four it currently reimburses. Stakeholders feel it's important to simplify the process for assessing and approving new PET imaging agents for reimbursement, particularly in light of several new ones coming down the pipeline. Many of these new agents will evaluate myocardial perfusion, as well as the pathophysiology of Alzheimer's disease and Parkinson's disease.

"To go indication by indication on all these new agents we expect to hopefully be approved over the next few years will be a bit cumbersome," said Frederic Fahey, president of the Society of Nuclear Medicine and Molecular Imaging (now SNMMI, formerly SNM).

Story Continues Below Advertisement

New & Refurbished C-Arm Systems. Call 702.384.0085 Today!

KenQuest provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fufill your equipment needs



SNMMI, in conjunction with the Medical Imaging and Technology Alliance, American College of Radiology, Council on Radionuclides and Radiopharmaceuticals, and World Molecular Imaging Society, are backing this request to remove a second layer of approval outside the FDA's. Discussions have been ongoing for the past year with CMS, and a formal letter was sent to the agency at the end of March.

CMS has a national coverage determination in place denying reimbursement for PET agents outside of its approved list.

"Once you've gone through the rather rigorous FDA process including showing efficacy, you've done a pretty decent job of showing the indications that are being recommended for that agent," said Fahey.

The letter that was submitted to CMS from the five agencies goes on to say that recent advances in imaging and CMS' past experience with PET coverage no longer support a clinical rationale for a national noncoverage policy for new PET agents that have undergone FDA review and approval.

"In my mind, the old way may have been reasonable for FDG. FDG is a pretty non-specific agent. It goes a lot of different places and is used for many different things. But I think as we move forward into molecular imaging, more targeted and hopefully more specific imaging for a particular patient, the indications are probably not going to be as broad and wide," said Fahey.

CMS is accepting public comments until Aug. 10 to determine whether to cover remaining uses of PET.

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED